Ignite Creation Date:
2025-12-25 @ 2:53 AM
Ignite Modification Date:
2026-03-02 @ 8:39 PM
Study NCT ID:
NCT02289833
Status:
COMPLETED
Last Update Posted:
2019-08-07
First Post:
2014-11-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-12-15
Start Date Type:
ACTUAL
Primary Completion Date:
2016-10-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-08-20
Completion Date Type:
ACTUAL
First Submit Date:
2014-11-04
First Submit QC Date:
None
Study First Post Date:
2014-11-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-10-24
Results First Submit QC Date:
None
Results First Post Date:
2017-11-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-07-23
Last Update Post Date:
2019-08-07
Last Update Post Date Type:
ACTUAL